bioTheranostics Launches Precision Medicine Biomarkers for Tumor Pathway Interrogation
Jan 31, 2012, 11:00 ET
SAN DIEGO, Jan. 31, 2012 /PRNewswire/ -- bioTheranostics, Inc., a bioMerieux company that develops innovative oncology diagnostic tests to drive personalized treatment, has introduced a new product line of high medical value biomarkers for response, resistance and pathway interrogation called PRECIS Precision Medicine by bioTheranostics(SM). Precision medicine, a new paradigm in cancer management, partners accurate diagnosis of primary tumor site and predictive biomarkers to drive targeted therapy. The PRECIS tests help oncologists predict potential response and evaluate underlying disease pathways as they consider targeted therapies.
The PRECIS product line includes biomarker profiles for non-small cell lung cancer and colorectal cancer and detects clinically relevant tumor biomarkers EGFR, ALK rearrangement, KRAS, BRAF, c-MET, PIK3CA and 10q23 deletion to aid in characterizing disease behavior and therapeutic effectiveness.
"An unmet need for targeted therapy treatments in metastatic cancer is accurate tumor classification plus knowledge of the activated signal transduction pathway driving cancer growth," said Richard Ding, Chief Executive Officer of bioTheranostics. "The use of CancerTYPE ID®, the leading molecular classifier to aid physicians in ascertaining tumor origin, and PRECIS Precision Medicine biomarkers has significant potential to improve cancer diagnosis and help oncologists efficiently formulate an optimal personalized treatment plan.
"The launch of PRECIS is a key milestone for bioTheranostics as the company moves to become an integrated diagnostic solution provider in cancer management," said Ding. "The PRECIS test menu provides cutting-edge tumor pathway information on therapeutic prediction and resistance mechanisms.
"We will continue to expand our testing menu as more predictive biomarkers demonstrate their clinical utility. Our physician customers have also indicated that the turnaround time for the test results was important in their clinical decisions. Our lab will respond to our client's needs by providing PRECIS test results within 7 to 10 days," Ding concluded.
Advancing Molecular Diagnostics in Oncology
bioTheranostics discovers, develops and commercializes molecular diagnostic tests for cancer patients. Leveraging its unique expertise in expression profiling and algorithm development, bioTheranostics provides innovative tests to the oncology community. The company operates a CLIA-certified, CAP-accredited diagnostic service laboratory in San Diego, CA to perform its proprietary molecular diagnostic tests: breastcancerindex, which is a prognostic test that provides quantitative risk assessment of distant recurrence in patients diagnosed with estrogen receptor positive and lymph node negative breast cancer; CancerTYPE ID, which uses the differential expression of 92 genes to aid in the determination of tumor site of origin and PRECIS Precision Medicine by bioTheranostics, which includes clinically relevant oncology biomarkers for comprehensive cancer management.
For more information, call 1-858-587-5870 or visit www.bioTheranostics.com.
Advancing Diagnostics to Improve Public Health
A world leader in the field of in vitro diagnostics for over 45 years, bioMerieux is present in more than 150 countries through 39 subsidiaries and a large network of distributors. In 2011, revenues reached euro 1.427 billion with 87% of sales outside of France.
bioMerieux provides diagnostic solutions (reagents, instruments, software) which determine the source of disease and contamination to improve patient health and ensure consumer safety. Its products are used for diagnosing infectious diseases and providing high medical value results for cancer screening and monitoring and cardiovascular emergencies. They are also used for detecting microorganisms in agri-food, pharmaceutical and cosmetic products.
bioMerieux is listed on the NYSE Euronext Paris market (Symbol: BIM – ISIN: FR0010096479).
Other information can be found at www.biomerieux.com
Tel: + 1 858 587 5890
Tel: + 011 33 6 13 94 51 14
SOURCE bioTheranostics, Inc.
Share this article